research Genetic analysis of the role of androgen metabolism in the pathogenesis of prostate cancer
Certain genetic markers can indicate a person's risk of developing prostate cancer.
Search
for
Sort by
Research
750-780 / 1000+ resultsresearch Health Canada has approved finasteride [Proscar; Merck Frosst] and doxazosin cotherapy
research Booby Trap: Cancer gene spurs production of DNA-assaulting chemicals that alert and defuse rescue molecule (Cancer; Oxidative damage)
The cancer gene c-Myc increases harmful chemicals that damage DNA and can lead to cancer, but antioxidants can reduce this damage.
research Oral contraceptives and risk of breast cancer in women aged 20–54 years
Long-term use of oral contraceptives, especially starting before age 20, may increase the risk of early-onset breast cancer.
research Pain in pancreatic cancer: A medical oncologist's view
Pancreatic cancer pain management is inadequate due to the disease's severity and limited effectiveness of treatments.
research Les cançons de l'escarni
Agaricus bisporus β-Glucan particles could effectively treat cervical cancer and offer antimicrobial and antioxidant benefits.
research Prostate cancer and androgenic alopecia: The role of finasteride as a dual agent
Finasteride treats hair loss and reduces prostate cancer risk.
research Exploring the historical stigma of spironolactone use in breast cancer survivors with alopecia
Spironolactone is safe for breast cancer survivors with alopecia and does not increase cancer risk.
research Androgenetic Alopecia and Thyroid Cancer: Coincidence or More?
The document suggests a possible link between hair loss and thyroid cancer, but doesn't provide definite proof.
research Faculty Opinions recommendation of Androgenetic alopecia and risk of prostate cancer: a systematic review and meta-analysis.
Hair loss at the top of the head is linked to prostate cancer, but other types of hair loss are not.
research 341 ANDROGENETIC ALOPECIA AT VARIOUS AGES AND PROSTATE CANCER RISK IN AN EQUAL ACCESS MULTIETHNIC CASE CONTROL SERIES OF VETERANS
Early baldness increases prostate cancer risk, radiotherapy and surgery have similar second cancer rates, and ALA may reduce prostate cancer risk.
research Selenium for preventing cancer
Selenium supplements do not prevent cancer and may increase certain health risks.
research Keratins in health and cancer: more than mere epithelial cell markers
Keratins help protect cells, aid in cancer diagnosis, and influence cancer behavior and treatment.
research Phenotypic Plasticity: Driver of Cancer Initiation, Progression, and Therapy Resistance
Understanding phenotypic plasticity is crucial for developing effective cancer therapies.
research Phase III randomised clinical trial comparing primary surgery versus neoadjuvant chemotherapy in advanced epithelial ovarian cancer with high tumour load (SCORPION trial): Final analysis of peri-operative outcome
Neoadjuvant chemotherapy followed by surgery leads to fewer severe complications and better quality of life than immediate surgery in advanced ovarian cancer patients with high tumor load.
research Tracing the cellular origin of cancer
Understanding where cancer cells come from helps create better prevention and treatment methods.
research Corneal Limbal Microenvironment Can Induce Transdifferentiation of Hair Follicle Stem Cells into Corneal Epithelial-like Cells
Hair follicle stem cells can become corneal-like cells, potentially helping restore vision.
research Hair and cancer chemotherapy: consequences and nursing care - a literature study
Chemotherapy-induced hair loss significantly affects patients' well-being, and nurses are key in helping them cope, but more research is needed to find effective treatments.
research Risk factors for prostate cancer: a case-control study in Greece
Urban living may increase prostate cancer risk, while early sexual activity might reduce it.
research Pegylated Liposomal Doxorubicin in the Treatment of Breast Cancer
PLD is an effective and safer alternative for treating breast cancer.
research Multicentric parallel phase II trial of the polo-like kinase 1 inhibitor BI 2536 in patients with advanced head and neck cancer, breast cancer, ovarian cancer, soft tissue sarcoma and melanoma. The first protocol of the European Organization for Research and Treatment of Cancer (EORTC) Network Of Core Institutes (NOCI)
BI 2536 had limited effectiveness against several advanced cancers and caused significant side effects.
research Selenium for preventing cancer
Selenium supplements do not prevent cancer and may have harmful effects.
research New agents for cancer chemoprevention
Over 30 potential cancer prevention treatments are being tested, with some showing promise in early research.
research Wedelolactone, a medicinal plant-derived coumestan, induces caspase-dependent apoptosis in prostate cancer cells via downregulation of PKCε without inhibiting Akt
Wedelolactone selectively kills prostate cancer cells without harming normal cells.
research Nanoparticle systems reduce systemic toxicity in cancer treatment
Nanoparticle systems make cancer treatment less toxic.
research Nonmelanoma skin cancer treated with electronic brachytherapy: Results at 1 year
HDR electronic brachytherapy effectively treats nonmelanoma skin cancer with good cosmetic results and minimal side effects.
research Chemotherapy-induced dermatological toxicity: frequencies and impact on quality of life in women’s cancers. Results of a prospective study
Chemotherapy often causes skin, nail, and hair side effects, significantly impacting quality of life.
research The Dark Side of 5α-Reductase Inhibitors' Therapy: Sexual Dysfunction, High Gleason Grade Prostate Cancer and Depression
5α-reductase inhibitors can cause sexual problems, higher risk of aggressive prostate cancer, and depression.
research Glibenclamide inhibits cell growth by inducing G0/G1 arrest in the human breast cancer cell line MDA-MB-231
Glibenclamide slows breast cancer cell growth by stopping cell division.
research Permanent scalp alopecia related to breast cancer chemotherapy by sequential fluorouracil/epirubicin/cyclophosphamide (FEC) and docetaxel: a prospective study of 20 patients
Some breast cancer chemotherapy can cause permanent hair loss.